1 December 2020 in Current Drug Metabolism
Background: Aldol reductase (AR) is the polyol pathway's main enzyme that portrays a crucial part in developing ‘complications of diabetes’ involving cataract, retinopathy, nephropathy, and neuropathy. These diabetic abnormalities are triggered tremendously via aggregation of sorbitol formation (catalyzed by AR) in the polyol pathway. Consequently, it represents an admirable therapeutic target and vast research was done for the discovery of novel molecules as potential AR inhibitors for diabetic complications. Objective: This review article has been planned to discuss an outline of diabetic complications, AR and its role in diabetic complications, natural compounds reported as AR inhibitors, and benefits of natural/plant derived AR inhibitors for the management of diabetic abnormalities. Results: The goal of AR inhibition remedy is to stabilize the increased flux of blood glucose and sorbitol via the ‘polyol pathway’ in the affected tissues. A variety of synthetic inhibitors of AR have been established such as tolrestat and sorbinil, but both of these face limitations including low permeability and health problems. Pharmaceutical industries and other scientists were also undertaking work to develop newer, active, and ‘safe’ AR inhibitors from natural sources. Therefore, several naturally found molecules were documented to possess a potent inhibitory action on AR activity. Conclusion: Natural inhibitors of AR appeared as harmless pharmacological agents for controlling diabetic complications. The detailed literature throughout this article shows the significance of herbal extracts and phytochemicals as prospective useful AR inhibitors in treating diabetic complications.
1 May 2021 in Current Drug Discovery Technologies
: Alcoholic and non-alcoholic fatty liver diseases have become a serious concern worldwide. Both these liver diseases have an identical pathology, starting from simple steatosis to cirrhosis and, ultimately to hepatocellular carcinoma. Treatment options for alcoholic liver disease (ALD) are still the same as they were 50 years ago which include corticosteroids, pentoxifylline, antioxidants, nutritional support and abstinence; and for non-alcoholic fatty liver disease (NAFLD), weight loss, insulin sensitizers, lipid-lowering agents and anti-oxidants are the only treatment options. Despite broad research in understanding the disease pathophysiology, limited treatments are available for clinical use. Some therapeutic strategies based on targeting a specific molecule have been developed to lessen the consequences of disease and are under clinical investigation. Therefore, focus on multiple molecular targets will help develop an efficient therapeutic strategy. This review comprises a brief overview of the pathogenesis of ALD and NAFLD; recent molecular drug targets explored for ALD and NAFLD that may prove to be effective for multiple therapeutic regimens and also the clinical status of these promising drug targets for liver diseases.
9 November 2026 in Innovative Medicine of Kuban
Background: Portal cavernoma, a complex vascular disease characterized by the formation of a branch structure because of portal vein thrombosis, remains a significant clinical concern. This study explores the current understanding of the molecular mechanism, including dysregulation of angiogenesis signaling, immunological chain reactions and impaired endothelial function for cavernoma development. Objective: There is no FDA-approved specific drug for portal vein complications. Hence objective of this review is to maximize treatment and enhance patient outcomes, by a collaborative effort, comprising gastrointestinal specialists, interventional radiologists and hepatobiliary surgeons to improve long-term results and quality of life for these patients. Methods: Drug therapies aimed at VEGF, or TGF-β, along with hypoxia-inducible elements, exhibit potential to manage portal cavernoma. Current biological findings have uncovered new pathways driving their origins, resulting in possible drug targets and novel treatment techniques. Growing approaches to treatment, mainly anti-angiogenic medications, focused on genetic therapy and immune system modulation, suggest the potential in addition to conventional blood coagulation, along with surgical techniques. Results: Current treatment strategies frequently rely on case reports that lack defined treatment standards. Long-term outcomes of various therapeutic techniques, optimal anticoagulation strategies and the involvement of endovascular or surgical therapies are all important areas that require additional research. Despite the serious clinical implications, portal cavernoma remains underrepresented in the literature. Conclusion: This review highlighted the requirement for necessary clinical understanding for management and further investigation into this complex disorder and also covers the gaps in understanding molecular mechanisms, utilizing standardized therapeutic strategies and focusing on individualized treatment plans for patients of portal cavernoma.